Autres langues Perseus Proteomics Inc.

Actions

4882

JP3836800007

Marché Fermé - Japan Exchange Autres places de cotation 08:00:00 31/05/2024			Varia. 5j.	Varia. 1 janv.
325 ^JPY	+5,18%		-0,61%	-47,41%

10/05	Perseus Proteomics Inc. annonce un retard dans la fin de l'essai clinique de phase I pour la polycythémie vénérienne	CI
14/02	Perseus Proteomics Inc. publie ses résultats pour les neuf mois clos le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Perseus Proteomics Inc. Announces on Delay in the End of Phase I Clinical Trial for Polycythemia Vera	10/05
Perseus Proteomics Inc. Reports Earnings Results for the Nine Months Ended December 31, 2023	14/02
Perseus Proteomics Inc. Announces on Delay in the End of Phase I Clinical Trial for Polycythemia Vera	02/02
Perseus Proteomics Inc. Reports Earnings Results for the Half Year Ended September 30, 2023	13/11
Perseus Proteomics Inc. Announces Completion of Patients Enrollment in Phase I Clinical Trial for Polycythemia Vera (PV)	20/10/23
Perseus Proteomics Inc. Announces Sales Launch of New Antibodies/Reagents	11/10/23
Perseus Proteomics, Inc. Announces Provision of Antibody Research Support Service Through Single Cell Cloning Technology	27/09/23
Perseus Proteomics Inc. Announces on Dosing of the First Patient in Phase I/II Clinical Trial for Aggressive NK-Cell Leukemia	22/09/23
Perseus Proteomics, Inc. Announces MOU Agreement on Joint Research on Super-Neutralizing Antibody with University of Toyama and Toyama Prefecture	29/08/23
Perseus Proteomics Inc. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2024	14/08/23
Perseus Proteomics Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	14/08/23
Perseus Proteomics Inc. Announces the Interim Report of Phase I Clinical Trial of PPMX-T003	29/05/23
Perseus Proteomics Inc. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2024	12/05/23
Perseus Proteomics Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	12/05/23
Perseus Proteomics Inc. Updates Financial Forecast for the Year 2022	25/04/23
Perseus Proteomics Inc. Announces That PMDA Has Finished Investigation of the Clinical Trial Notification of the Phase I/II Investigator-Led Clinical Trial	27/03/23
Perseus Proteomics Inc. Submits the Clinical Trial Notification of the Phase I/II Investigator-Led Clinical Trial Among Aggressive Nk-Cell Leukemia Patients Using In-Development Anti-Transferrin Receptor Antibody PPMX-T003 as A Therapeutic to the PMDA by Hiroshima University Hospital	15/03/23
Perseus Proteomics Inc. Reports Earnings Results for the Nine Months Ended December 31, 2022	13/02/23
Perseus Proteomics Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023	13/02/23
Perseus Proteomics Inc. Announces Extension of Phase I Clinical Trial of PPMX-T003 among Polycythemia Vera Patients	07/02/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Perseus Proteomics Inc.

Actions

4882

JP3836800007

Autres langues

Filtres